NCT00529763 - Dasatinib in Imatinib Resistant/Intolerant Chinese CML (Chronic and Advanced Phase) Subjects | Biotech Hunter

Enrollment

121

Participants

Timeline

Start Date

November 17, 2007

Primary Completion Date

June 17, 2009

Study Completion Date

April 20, 2022

Conditions

Leukemia

Interventions

DRUG

Dasatinib

Tablets, Oral, 70 mg BID (AD CML) or 100 mg QD (Chronic CML), once or twice daily dependent on disease stage, until subjects meet discontinuation (DC) criteria for study

Trial Locations (14)

100044

Local Institution, Beijing

200025

Local Institution, Shanghai

200433

Local Institution, Shanghai

210029

Local Institution, Nanjing

215006

Local Institution - 0008, Suzhou

Local Institution, Suzhou

300020

Local Institution, Tianjin

310003

Local Institution - 0009, Hangzhou

Local Institution, Hangzhou

350001

Local Institution - 0004, Fuzhou

Local Institution, Fuzhou

510515

Local Institution, Guangzhou

610041

Local Institution, Chengdou

Local Institution, Chengdu